Pay in 4 interest-free payments of $7.13 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Naltrexone SR/Bupropion SR (Contrave): a new approach to weight loss in obese adults
If a product causes harm, there is no regulatory recourse, no product liability in most cases, and no guarantee that the vendor will still be in business when problems emerge
Capital Rxs goal is to ensure that members who are true candidates for GLP-1s have access to these treatments
Document oral iron failure: Many payers require documentation of iron failure or not tolerated with oral iron
For researchers comparing tirzepatide against other incretin compounds, our product catalog includes semaglutide, retatrutide, and other GLP-1 pathway peptides
Q1 2025 revenue reached $790 million, up 99% YoY
US$ 24.51
US$ 26.81
US$ 25.80
US$ 26.44
US$ 24.59
